Salbutamol
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Salbutamol: From Bronchodilation (Asthma/COPD) to Papillary Conjunctivitis
One-Sentence Summary
Salbutamol is a β2-adrenergic receptor agonist bronchodilator whose established use in asthma and COPD is reflected throughout this evidence pack’s own mechanistic notes. The TxGNN model’s single highest-scoring prediction points to Papillary Conjunctivitis, but this candidate currently has no clinical trials and no published literature supporting it — it is a pure embedding-score signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in India regulatory filings (drug is unmarketed there); per this pack’s own mechanistic notes, Salbutamol is a β2-agonist bronchodilator for asthma/COPD |
| Predicted New Indication | Papillary Conjunctivitis |
| TxGNN Prediction Score | 99.9964% (rank 143 of all candidates) |
| Evidence Level | L5 |
| India Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action documentation for Salbutamol is not available in this evidence pack (data gap DG002). Based on what is captured in the pack’s own rationale fields, Salbutamol is a short-acting β2-adrenoceptor agonist whose bronchodilator effect in asthma/COPD is well established — this is corroborated by the strong, high-evidence-level entries for bronchitis (L1) and obstructive lung disease (L1) elsewhere in this same candidate set.
For the top-ranked prediction itself, however, the model’s own rationale is explicit that there is no direct mechanistic link between bronchial smooth-muscle β2-agonism and the allergic/contact inflammatory pathology of papillary conjunctivitis — the high score reflects embedding similarity only, not biological plausibility for this specific indication.
That said, a related candidate in this same evidence pack (rank 8, atopic conjunctivitis, L4) is supported by animal-model literature showing that topically applied β2-agonists — including salbutamol — can suppress immediate allergic conjunctivitis and exert local anti-inflammatory activity on conjunctival tissue (PMID 3666475; PMID 2906082). This suggests a plausible class-level mechanism for ocular surface inflammation that could indirectly lend biological hypothesis-generating support to papillary conjunctivitis, even though no study has tested this specific diagnosis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Salbutamol currently has no registered licenses in India (market status: Not marketed; total registrations on file: 0).
Safety Considerations
Structured warnings and contraindications data is not available for Salbutamol in this evidence pack; please refer to the package insert for that information.
Drug-drug interaction (DDI) data, however, is available — 754 total interactions on file. Representative entries:
| Interacting Drug | Interaction Level | Source |
|---|---|---|
| Acarbose | Moderate | DDInter |
| Isometheptene | Moderate | DDInter |
| Famotidine | Moderate | DDInter |
| Epinephrine | Moderate | DDInter |
| Albiglutide | Moderate | DDInter |
| Acetohexamide | Moderate | DDInter |
| Alogliptin | Moderate | DDInter |
| Bisacodyl | Moderate | DDInter |
| Canagliflozin | Moderate | DDInter |
| Castor oil | Moderate | DDInter |
| Chlorpropamide | Moderate | DDInter |
| Cisapride | Moderate | DDInter |
| Clarithromycin | Moderate | DDInter |
| Dapagliflozin | Moderate | DDInter |
| Diethylpropion | Moderate | DDInter |
| Hydrocortisone | Minor | DDInter |
| Beclomethasone dipropionate | Minor | DDInter |
| Betamethasone | Minor | DDInter |
| Budesonide | Minor | DDInter |
| Dexamethasone | Minor | DDInter |
Notably, several antidiabetic agents (SGLT2 inhibitors, sulfonylureas, DPP-4 inhibitors) show Moderate-level interactions, consistent with salbutamol’s known hyperglycemic effect — this warrants attention if this candidate advances toward any patient-facing use.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked TxGNN prediction (papillary conjunctivitis, score 99.9964%) has zero supporting clinical trials or literature, and the model’s own rationale states there is no direct mechanistic link — this is an L5, model-only signal. Note that within this same evidence pack, two other candidates (bronchitis, obstructive lung disease) are rated L1/Proceed with Guardrails, but these represent Salbutamol’s already-known bronchodilator indication rather than a novel repurposing opportunity.
To proceed, the following is needed:
- TFDA/India-equivalent product label with warnings and contraindications (currently Blocking data gap DG001)
- Confirmed mechanism-of-action documentation from DrugBank (data gap DG002)
- If pursuing the ocular-inflammation hypothesis: preclinical/mechanistic studies specific to papillary conjunctivitis (the related atopic conjunctivitis animal data, PMID 3666475/2906082, could inform study design)
- Given zero India market presence, a regulatory pathway assessment would be required before any clinical development
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.